National and regional population-based registries are, provided diagnostic accuracy and full
coverage of the target population, indispensible tools for epidemiological research. Chronic …

Background Imatinib slows development of chronic myeloid leukemia (CML). However,
available information on morbidity and mortality is largely based on sponsored trials …

Atypical chronic myeloid leukemia (aCML) shares clinical and laboratory features with CML,
but it lacks the BCR-ABL1 fusion. We performed exome sequencing of eight aCMLs and …

The availability of several BCR-ABL1 tyrosine kinase inhibitor (TKI) options means
physicians and patients can select the most appropriate treatment for a patient with chronic …

Patients with chronic myeloproliferative neoplasms, including essential thrombocythemia
(ET), polycythemia vera (PV), and chronic myeloid leukemia (CML), are at increased risk of …

Given that tyrosine kinase inhibitors (TKI s) have dramatically improved the survival of
patients with chronic myeloid leukaemia (CML), we were interested in examining the …

Abstract Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the
introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent …

Hairy cell leukemia (HCL) is a chronic B-cell leukemia noted for an indolent course that
ultimately results in cytopenias and massive splenomegaly. Whereas treatment with the …

The initial treatment for chronic myeloid leukemia in chronic phase (CP‐CML) represents a
complex process, which includes a prompt and precise diagnosis, the choice among three …

Background Cancer survivors are at risk of developing second and subsequent primary
cancers, referred to as multiple primary cancers (MPCs). It is not clear whether the risk of …